Literature DB >> 30248162

Chronic Pruritus: A Review of Neurophysiology and Associated Immune Neuromodulatory Treatments.

J M Patel1, H Dao2.   

Abstract

Chronic pruritus remains a difficult condition to treat with many non-specific therapeutic options. Recent scientific discoveries have elucidated the physiology associated with pruritus. Combined with clinical and experimental trials with immune-modulatory agents, chronic pruritus now has novel treatment options with known mechanisms of action. This review goes over recent scientific progress in understanding the molecular mechanisms governing pruritus, the cross-talk between the immune and nervous systems that regulate itch, and central nervous pathways and projections affected by itch. In light of these recent discoveries, we briefly discuss a growing body of data from relevant clinical trials investigating immunomodulatory drugs targeting specific interleukin receptors (IL-4/13/31) and intracellular signaling (e.g., Janus kinase) pathways. We focus on the physiological processes that control this complex physical and emotional experience, as well as the role of newer drugs used to treat chronic itch.

Entities:  

Keywords:  chronic pruritus; neuro-immune interaction; dorsal root ganglion; IL-4; IL-13; IL-31; IL-4Ra; dupilumab; ruxolitinib; tofacitinib; nemolizumab; Janus kinase

Mesh:

Substances:

Year:  2018        PMID: 30248162

Source DB:  PubMed          Journal:  Skin Therapy Lett        ISSN: 1201-5989


  1 in total

1.  Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Authors:  Saadet Inan; Alvaro Torres-Huerta; Liselotte E Jensen; Nae J Dun; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2019-09-27       Impact factor: 4.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.